SCHEMBL6518864

SCHEMBL6518864

COc1ccccc1CNc1ccc2c(=O)[nH]c3ncccc3c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.51
PARP1 P09874 1/20 0.51
ABL1 P00519 1/20 0.47
SRC P12931 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
TSHR P16473 1/20 0.46
CYP2C19 P33261 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CLK4 Q9HAZ1 1/20 0.46
HCAR2 Q8TDS4 1/20 0.45
EGFR P00533 2/20 0.45
PDE9A O76083 2/20 0.45
HIF1A Q16665 1/20 0.45
BRD4 O60885 2/20 0.43
ATM Q13315 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6521905 0.85 AURKA (0.55) AURKAPARP1ABL1SRCMEN1
SCHEMBL6525424 0.85 ABL1 (0.57) ABL1SRCMEN1KMT2AEGFR
SCHEMBL3454715 0.83 AURKA (0.55) AURKAPARP1MEN1KMT2ACYP1A2
SCHEMBL3453866 0.83 AURKA (0.55) AURKAPARP1MEN1KMT2AHCAR2
SCHEMBL3455169 0.83 AURKA (0.55) AURKAPARP1ABL1SRCCYP1A2
SCHEMBL6525348 0.83 AURKA (0.55) AURKAPARP1EGFRGAA
SCHEMBL6519121 0.83 AURKA (0.55) AURKAPARP1SRCMEN1KMT2A
SCHEMBL12846643 0.81 AURKA (0.52) AURKAPARP1KMT2AL3MBTL1GAA
SCHEMBL6527186 0.81 MAPT (0.51) AURKAPARP1MEN1KMT2AHSD17B10
SCHEMBL6523440 0.81 AURKA (0.55) AURKAPARP1MEN1KMT2ABRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 AURKA 538/4885PARP1 1693/4885ABL1 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.